Mercury Bio, a Santa Fe, NM-based biotech company working in the area of targeted molecular drug delivery, raised $2M in Seed funding.
The backers were not disclosed.
The company intends to use the funds to expand operations and its business reach.
Led by CEO Bruce McCormick, Mercury Bio is developing a biomolecular drug delivery platform. Using a novel system for drug encapsulation in natural vesicles, their technology enhances drug efficacy while reducing side effects by employing cell-specific targeting. The result is a drug delivery system in a scalable, low-cost production platform that will use RNA therapeutics and small molecule drugs.
The company also added John Tomes as Finance Director. He brings experience in capital markets and company building. Tomes most recently served as a Senior Partner with Hawthorn Equity Partners (Toronto & Chicago), and has more than 25 years of private equity and early-stage investment experience across four funds managing in excess of $450M of capital. Prior to that, he was a Managing Director at GE Capital and responsible for sourcing and managing over 70 leveraged lending and equity investments totaling $5.5 BN of capital and managing offices in Chicago, San Francisco, Los Angeles and Seattle. Tomes also has served on more than 15 boards, and been involved in multiple company sale events, IPOs, restructurings, and mergers. He holds a BA from Kenyon College in Biology, and an MBA from the University of Chicago.
FinSMEs
30/08/2023